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Note 




Myriad Genetics, Inc. (Myriad), a young1 genetics 
company, specializes in linking human genes to diseases and 
establishing the likelihood of a person expressing2 a gene 
developing those diseases.3 Myriad’s profitable4 business of 
testing customers for diseases linked with these genes has 
rested upon Myriad’s ability to monopolize the testing market 
by patenting the discovered genes and the testing process. 
Between 1997 and 2000, Myriad was issued seven patents 
related to the BRCA1 and BRCA2 genes.5 These genes, due to 
Myriad’s research, have been strongly linked to susceptibility 
to hereditary breast cancer.6 Myriad’s seven patents together 
© 2011 Peter Edwards. 
* University of Minnesota Law School J.D. Candidate, 2012. 
 1. Founded in May, 1991. Myriad Genetics — About, MYRIAD GENETICS 
AND LAB., http://www.myriad.com/about/ (last visited Nov. 24, 2010). 
 2. In biological terms, a person is said to express a gene when that gene 
leads to distinguishable traits in that person. SOLOMON, ET AL., BIOLOGY 261 
(Nedah Rose et al. eds., 6th ed. 2002). 
 3. Id. 
 4. MYRIAD GENETICS, 2010 ANNUAL SHAREHOLDER REPORT 2 (Sept. 21, 
2010). 
 5. U.S. Patent No. 5,693,473 (filed June 7, 1995); U.S. Patent No. 
5,709,999 (filed June 7, 1995); U.S. Patent No. 5,710,001 (filed June 7, 1995); 
U.S. Patent No. 5,747,282 (filed June 7, 1995); U.S. Patent No. 5,753,441 (filed 
Jan. 5, 1996); U.S. Patent No. 5,837,492 (filed Apr. 29, 1996); U.S. Patent No. 
6,033,857 (filed Mar. 20, 1998). 
 6. Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office 
(Myriad), 702 F. Supp. 2d 181, 185 (S.D.N.Y. 2010). 
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give Myriad a monopoly on any research and testing related to 
these genes.7 Without competition, Myriad has the ability to 
control the costs of all such tests, potentially driving the cost 
higher than some patients can afford.8 In May 2009, a 
complaint against the United States Patent and Trademark 
Office (USPTO) and Myriad was filed in the United States 
District Court for the Southern District of New York by, among 
others, the Association for Molecular Pathology.9 In the 
resulting case, Association for Molecular Pathology v. United 
States Trademark Office and Myriad Genetics (“Myriad”), 
plaintiffs attempted to invalidate Myriad’s seven patents,10 
which would effectively terminate Myriad’s monopoly rights on 
testing related to the BRCA1/BRCA2 genes. The district court 
agreed with plaintiffs that neither the genes nor the testing 
methods were patent eligible and invalidated all seven 
patents.11 Myriad appealed to the Court of Appeals for the 
Federal Circuit on June 16, 2010.12 The arguments in the 
Myriad case surrounding these patents have hurled genetic 
diagnosis to the forefront of intellectual property law and 
medicine. 
Genetic research, treatment, and diagnostic methods are 
growing extraordinarily important as medicine evolves. This 
has led to a shift in patenting biotechnology that Congress 
could not have foreseen when last amending the Patent Act in 
1952.13 Without incentives to develop medical innovations, 
private biotech companies will likely cease much of the 
research that results in new diagnostic tests, treatments, and 
cures for diseases such as breast cancer. The extent to which 
patent law should incentivize this research at the expense of 
innovations immediately being placed in the public domain is 
an issue central to the Myriad case. 
 7. Id. at 212–213. 
 8. Id. at 203. 
 9. Id. at 186. 
 10. Id. at 184. 
 11. Id. at 183. 
 12. Myriad Defendant’s Notice of Appeal at 1, Ass’n for Molecular 
Pathology v. Myriad Genetics Inc., No. 2010-1406 (Fed. Cir. Oct. 22, 2010). 
 13. The Patent Act of 1952 was the last comprehensive amendment to 35 
U.S.C. § 100 (1952). Since then Congress has found it necessary to update the 
Patent Act to keep up with the developing field of biotechnology. E.g. 35 U.S.C. 
§ 103(b) (1995) (establishing special rules for determining obviousness for 
biotechnological process patents). 
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The goal of this Comment is to explain the policy concerns 
at issue in Myriad and relate them to the options available to 
the Court of Appeals for the Federal Circuit in light of the 
current state of patent law. The Background section provides 
information on the relevant medical, biological, and legal 
issues. The Case Summary section describes the facts of 
Myriad and the district court’s analysis and ruling. The 
Analysis section critiques the district court’s analysis, the 
analysis of the main and other interested parties, and suggests 
resolutions of all issues faced by the court. This Comment 
concludes that both genes as compositions of matter, and 
diagnostic testing methods utilizing those genes, are patent 
eligible, but that Congress must clarify patent law’s stance on 
the issues before further controversy arises. 
II. BACKGROUND 
A. THE IMPACT OF CANCER 
The cost of treating and researching cancer are powerful 
influences on our economy. In 2005, Medicare paid 
approximately four billion dollars to oncologists for drugs, and 
approximately seven hundred million dollars for 
chemotherapy.14 Notwithstanding the significant investment in 
fighting cancer, it remains tremendously deadly, requiring 
continued investment. By 2007, cancer had become the second 
highest cause of death in the United States.15 Further, between 
1998 and 2007, total U.S. incidences of cancer had dropped by 
only 0.9 percent,16 and grew by 1.9 percent in people above 
sixty-five between 1950 and 2007.17 On average, the chance of 
 14. Letter from Laura A. Dummit, Dir., Health Care—Medicare Payment 
Issues to The Honorable Joe Barton, Chairman of the Comm. on Energy and 
Commerce, House of Representatives 12, 14 (Dec. 1, 2004) (on file with 
author). These figures include, presumptively, fees for drugs and oncologist 
visits. 
 15. NAT’L CANCER INST., SURVEILLANCE EPIDEMIOLOGY AND END 
RESULTS, SEER CANCER STATISTICS REVIEW 1975–2007: LEADING CAUSES OF 
DEATH IN U.S., 1975 VS. 2007 (Nov. 2009), available at 
http://seer.cancer.gov/csr/1975_2007/results_merged/topic_lead_cod.pdf. 
 16. NAT’L CANCER INST., SURVEILLANCE EPIDEMIOLOGY AND END 
RESULTS, SEER CANCER STATISTICS REVIEW 1975–2007:  SEER INCIDENCE 
AND U.S. MORTALITY TRENDS BY PRIMARY CANCER SITE AND SEX 1 (Nov. 
2009), available at 
http://seer.cancer.gov/csr/1975_2007/results_single/sect_01_table.07_2pgs.pdf. 
 17. NAT’L CANCER INST., SURVEILLANCE EPIDEMIOLOGY AND END 
RESULTS, SEER CANCER STATISTICS REVIEW 1975–2007:  58-YEAR TRENDS IN 
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dying younger than the average life expectancy increases by 
forty-four percent once cancer is contracted.18 Estimates 
indicate that a person living in the United States in 2007 had a 
more than twenty percent risk of dying of cancer.19 
Breast cancer makes up a large portion of cancer 
incidences. Malignant breast cancer alone is the second most 
commonly diagnosed type of cancer, and malignant and in situ 
breast cancer combined are the most frequently diagnosed.20 
More deaths result from breast cancer than any other cancer 
except lung cancer,21 even though breast cancer has an 89 
percent survival rate.22 Breast cancer is the most common 
cancer in younger persons23 and disproportionally affects 
women.24 It is understandable that litigation concerning this 
disease would have an effect on a significant proportion of the 
United States population. 
B. THE BIOLOGY OF INHERITANCE 
Given the technical nature of the dispute between the 
U.S. CANCER DEATH RATES 1 (Nov. 2009), available at 
http://seer.cancer.gov/csr/1975_2007/results_single/sect_01_table.02.pdf. 
 18. NAT’L CANCER INST., SURVEILLANCE EPIDEMIOLOGY AND END 
RESULTS, SEER CANCER STATISTICS REVIEW 1975–2007: AGE-ADJUSTED 
SEER INCIDENCE AND U.S. DEATH RATES AND 5-YEAR RELATIVE SURVIVAL 
(PERCENT) 1 (Nov. 2009) [hereinafter AGE-ADJUSTED SEER INCIDENCE], 
available at 
http://seer.cancer.gov/csr/1975_2007/results_single/sect_01_table.04_2pgs.pdf. 
 19. NAT’L CANCER INST., SURVEILLANCE EPIDEMIOLOGY AND END 
RESULTS, SEER CANCER STATISTICS REVIEW 1975–2007: LIFETIME RISK 
(PERCENT) OF DYING FROM CANCER BY SITE AND RACE/ETHNICITY 1 (Nov. 
2009), available at 
http://seer.cancer.gov/csr/1975_2007/results_single/sect_01_table.04_2pgs.pdf. 
 20. NAT’L CANCER INST., SURVEILLANCE EPIDEMIOLOGY AND END 
RESULTS, SEER CANCER STATISTICS REVIEW 1975–2007: LIFETIME RISK 
(PERCENT) OF BEING DIAGNOSED WITH CANCER BY SITE AND RACE/ETHNICITY 
1 (Nov. 2009) [hereinafter RISK OF BEING DIAGNOSED], available at 
http://seer.cancer.gov/csr/1975_2007/results_single/sect_01_table.14_2pgs.pdf. 
 21. Id. 
 22. AGE-ADJUSTED SEER INCIDENCE, supra note 18. These unexpected 
numbers illustrate the immense number of breast cancer incidences among 
other, deadlier cancers. 
 23. NAT’L CANCER INST., SURVEILLANCE EPIDEMIOLOGY AND END 
RESULTS, SEER CANCER STATISTICS REVIEW 1975–2007: U.S. PREVALENCE 
COUNTS, INVASIVE CANCERS ONLY, JANUARY 1, 2007, at 4 (Nov. 2009), 
available at 
http://seer.cancer.gov/csr/1975_2007/results_single/sect_01_table.21_2pgs.pdf. 
 24. RISK OF BEING DIAGNOSED, supra note 20. 
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parties, a basic understanding of genetic inheritance is 
required before analyzing the issues. Biologically, inheritance 
is a function of person’s DNA,25 which is handed down from 
previous generations.26 DNA is composed of a long strand of 
sequential bases: adenine, guanine, thymine, and cytosine.27 
These bases are small, ring or figure-eight shaped molecules 
made up of 15 assorted carbon, nitrogen, oxygen and hydrogen 
atoms.28 The specific sequence of these bases is passed down to 
a person from that person’s parental generation; it determines 
development by dictating which proteins that person will 
produce.29 It follows, then, that determining the sequence of 
bases in a person’s DNA will uncover the genetic traits that 
person has inherited. 
However, much of a person’s DNA is not translated into 
proteins; this DNA is termed non-coding.30 Therefore, 
determining a person’s genes is a more effective method of 
determining a person’s inherited traits.31 Genes are the 
portions of a person’s DNA that are eventually expressed, i.e. 
translated into proteins.32 The genes of a person’s DNA are 
“read” to form RNA by a process known as transcription.33 The 
type of RNA that carries information from genes is known as 
messenger RNA (mRNA).34 mRNA is composed of the base 
sequences of a particular gene, but can itself be broken down 
into introns and exons.35 Introns are noncoding sequences of 
mRNA; exons eventually dictate what proteins an organism 
will produce and thus how that organism will develop.36 This 
occurs in a process called translation, during which the exons of 
a sequence of mRNA are “read” to determine the sequence in 
which to assemble amino acids to form a protein.37 However, 
before this occurs, the mRNA formed in transcription must be 
 25. SOLOMON, supra note 2 at 244. 
 26. Id. at 217. 
 27. Id. at 247. 
 28. Id. at 249. 
 29. Id. at 261. 
 30. Id. at 264, 266. 
 31. See id. at 218. 
 32. Id. at 278. 
 33. Id. at 265. 
 34. Id. at 264. 
 35. Id. at 275. 
 36. Id. 
 37. Id. 
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processed, at which point the introns are removed.38 The 
remaining exons are translated into specific proteins,39 and 
those specific proteins determine how an organism will 
develop.40 Therefore, by removing the regions of a person’s 
DNA that are not genes and the introns from the remaining 
genes by simulating transcription and mRNA processing, one 
can discover, from the exons that remain, the exact proteins 
that person will produce. Further, by running the processed 
mRNA through a reaction known as reverse transcription, it is 
possible to produce complementary DNA (cDNA), a stable 
template of the exons that exhibit those proteins.41 
If a person inherits DNA that has been changed, or 
mutated, that change may be reflected in that person’s DNA if 
the mutation occurs on an exon.42 This will change a person’s 
physical development, which could have disastrous results.43 
Most mutations will not be expressed because they occur in the 
non-coding portion of a person’s DNA that are either (1) not 
transcribed to RNA, or (2) occur in the introns, and thus are not 
translated into proteins.44 However, mutations such those on 
the BRCA1 gene and the BRCA2 gene have effects that are not 
easily noticed. The BRCA1 and BRCA2 genes have been linked 
to susceptibility to breast cancer,45 and therefore changes in a 
person’s development as a result of a BRCA1 or BRCA2 
mutation could significantly increase a person’s likelihood of 
developing the disease. Furthermore, these mutations may be 
passed down to future generations, creating the same increased 
likelihood in a person’s children.46 
DNA is reproduced in an organism, but geneticists are also 
able to produce it in greater volume using the polymerase chain 
reaction (PCR).47 In PCR, double-stranded DNA48 is separated 
 38. Id. 
 39. Id. 
 40. Id. 
 41. Id. at 306. 
 42. Id. at 279. 
 43. Id. 
 44. See id. at 264, 266. 
 45. Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office 
(Myriad), 702 F. Supp. 2d 181, 185 (S.D.N.Y. 2010). 
 46. See SOLOMON ET AL., supra note 2, at 217. 
 47. SOLOMON ET AL., supra note 2, at 307. 
 48. DNA is naturally found in a double helix form. See id. at 247. 
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into two single strands, at which point primers,49 DNA bases, 
and replication enzymes50 are added to the DNA mixture.51 
These components combine to duplicate each strand of DNA, 
doubling the amount of DNA in the mixture.52 With proper 
enzymes and an adequate supply of components, this process 
can be repeated indefinitely, each time doubling the amount of 
DNA.53 
It follows that, because mutations are changes in the 
sequences of bases in a person’s DNA, a person with a mutated 
gene will have a different DNA sequence than a person with 
the “normal” or “baseline” gene. To determine the sequence of a 
baseline gene, geneticists perform a special method of PCR 
using both regular bases and dideoxynucleotides, synthetic 
bases that attach to a single strand of DNA just as to an 
ordinary base, but that stop replication once attached to the 
DNA strand.54 With enough starting strands and enough bases, 
there will be a strand produced with the dideoxynucleotide at 
every position of the sequence.55 The segments are organized 
from shortest to longest, and the last base of each segment 
length are recorded. 56 For a simplified example, if a strand had 
the sequence ACGT, the process would result in four groups of 
segments. By counting the groups of segments, it would become 
clear that the total segment length is four bases. Segments in 
the first group would be one base long (A) with the As 
radiated.57 Segments in the second group would be two bases 
 49. A primer is a short sequence of RNA bases that attach to a strand of 
DNA to mark the start point of replication. They are replaced by DNA bases 
shortly. See id. at 253. 
 50. There are several enzymes involved in DNA replication, specific 
knowledge of which is not necessary here. See generally id. at 252–53. 
 51. Id. at 307. 
 52. Id. 
 53. Id. 
 54. Id. at 309. 
 55. Therefore, if the target sequence was one-hundred bases long, the 
result would be at least one strand produced corresponding to each of the 
hundred positions. Id. 
 56. Ordering by segment length and recording of terminal bases is 
performed using gel electrophoresis and autoradiography respectively. Gel 
electrophoresis and autoradiography are processes by which very small 
compounds can be separated and identified. No further understanding is 
relevant here. Id. at 308–09. 
 57. Autoradiography radiates the end bases of a strand, making the 
identity of the base at the end of the strand in each group easily discernable. 
Id. 
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long (AC) with the Cs radiated. Segments in the third group 
would be three bases long (ACG) with the Gs radiated, and so 
on. When this process is completed, the total segment length is 
known, the base for each position of the segment is discovered, 
and thus the sequence of the entire segment is known.58 
Fortunately, PCR (and thus, dideoxynucleotide PCR) can 
be performed on only the target sequence to be replicated, so 
long as the primers (short segments at the beginning of a gene 
of recognized base pattern) for the sequence are known.59 Thus, 
if geneticists are able to locate the gene they wish to sequence 
and/or replicate, they will be able to target that gene 
specifically for sequencing and/or replication.60 Therefore, if the 
sequence of a baseline gene is known, a specific person’s gene 
sequence can be compared to that baseline gene sequence to 
identify any points at which the bases differ.61 
C. LEGAL PRECEDENT OF PATENTING GENES 
The precise protection rights afforded to a holder of a 
patent of a human gene are hard to determine. For example, 
the USPTO claims that while genes are patentable, the 
sequences themselves and the underlying genetic information 
are not.62 It is not clear what the researcher is patenting in a 
gene, however, if not genetic information. The USPTO’s 
explanation of a patent holder’s rights do not provide much 
clarification. The USPTO claims that the patent holder has the 
right to exclude all others from any use of that gene,63 but also 
that the patent holder must promote discovery of other uses of 
the gene by other researchers.64 These other uses, according to 
the USPTO, would be patentable by the discoverers of those 
uses as an improvement on an existing invention.65 The 
USPTO does not explain how non-patent-holding researchers 
would be able to discover new uses for a gene when the patent 
 58. Id. at 309. 
 59. Id. at 307. 
 60. Id. 
 61. These points of differing bases would represent mutations in the 
person’s gene. 
 62. U.S. PATENT & TRADEMARK OFFICE, DEP’T OF COMMERCE, RIN 0651-
AB09, UTILITY EXAMINATION GUIDELINES 1093 (2001). 
 63. Id. at 1095. 
 64. Id. at 1094. 
 65. Id. at 1095. 
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holder has a right to ban all research on the gene.66 
Congress has the power to “promote the Progress of 
Science and useful Arts, by securing for limited Times to 
Authors and Inventors the exclusive Right to their respective 
Writings and Discoveries.”67 Pursuant to these objectives, 
Congress passed the Patent Act of 1836, which established the 
USPTO as the initial deciding body for all patent 
determinations, established a numerical system to track 
patents, and established the patent eligibility criteria.68 From 
that point on, “any person or persons having discovered or 
invented any new and useful art, machine, manufacture, or 
composition of matter, or any new and useful improvement on 
any art, machine, manufacture, or composition of matter . . .” 
could be granted patent protection.69 In order to receive a 
patent, an invention or discovery must be determined to be (1) 
patent eligible, and (2) patentable.70 Whether an invention is 
eligible for a patent is determined by the patent protection 
assigned to that type of invention.71 Whether an invention is 
patentable, on the other hand, depends on the specific 
properties and history of that particular invention, not the field 
in which the invention falls.72 Therefore, for an invention to be 
patented, it must (1) fall into a class of inventions to which 
patent protection can be assigned, and (2) comply with 
statutory provisions regarding the properties of that particular 
 66. It is worthy of note that § 271 of the Patent Act provides an 
experimental use exception which protects researchers of patented 
compounds, but only if they begin their research with a reasonable belief that 
the research, if successful, will result in information relevant to a new drug 
application to the Food and Drug Administration. 35 U.S.C. § 271 (2010); 
Merck KGAA v. Integra Lifesciences I, Ltd., 545 U.S. 193, 208 (2005). While 
this exception is broad, the Court held that a research must have an intended 
physiological effect, and a reason to believe the research would produce that 
effect. General exploratory research, therefore, is not protected. Merck, 545 
U.S. at 205–06. 
 67. U.S. CONST. art. I § 8, cl. 8. 
 68. Patent Act of 1836, 5 Stat. 117, (a), § 5–6 (1836). 
 69. Patent Act of 1836, 5 Stat. 117, §6 (1836); 35 U.S.C. § 100 (2006). 
Patent protection did not originate with the establishment of the USPTO, nor 
with an act of Congress. Even before the Constitution was ratified, state 
patent protection was available. Sears, Roebuck & Co. v. Stiffel Co., 376 U.S. 
225, 228 (1964). Additionally, some federal patent protection existed after 
1790. Id. at 229. 
 70. 35 U.S.C. § 101–02 (2006). 
 71. See 35 U.S.C. § 101 (2006). 
 72. See 35 U.S.C. § 102 (2006). 
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invention.73 The invention must be found by the examiner to be 
novel74 and non-obvious75 and the inventor must be able to 
show that he or she is the actual inventor.76 
When the Patent Act was passed, the phrase “new and 
useful art” was written to refer to a method by which 
something was done. It now has been replaced by the phrase 
“new and useful process” to reflect this meaning.77 Therefore, 
according to the Patent Act, an inventor can patent both a 
compound (a composition of matter) and the process by which 
that compound is made. Further, in certain biotechnical fields, 
a process and a composition of matter that may otherwise have 
been found to be too obvious to be patentable may still be 
patentable if, for example, the process and the composition are 
claimed in the same application.78 
Patenting chemical compounds is far from a matter of first 
impression for the USPTO or the courts.79 Indeed, even 
patenting chemical compounds that were purified but are 
otherwise unchanged from the compound found in nature is not 
a new subject.80 Since these early patents, many patents have 
been issued for chemical compounds.81 These compounds were 
often extractions from living organisms, whether plant or 
animal.82 This eventually led to patenting the organisms 
themselves: in May of 1930, Congress passed the Plant Patent 
Act, enabling discoverers of new plants to achieve patent 
protection for their discoveries, provided they had asexually 
reproduced the plants.83 This was a milestone for patent law, 
 73. See 35 U.S.C. §§ 101–02 (2006). 
 74. In order to be novel, the process or composition of matter claimed 
must not be publicly known. See 35 U.S.C. § 102 (2006). 
 75. To be non-obvious, the necessary innovation from prior inventions to 
arrive at the new invention must not be clear to a person well versed in the 
field from which the invention derives. 35 U.S.C. § 103(a) (2006). 
 76. 35 U.S.C. § 102(f) (2006). 
 77. Patent Act of 1836, 5 Stat. 117, § 6 (1836); 35 U.S.C. § 101 (2006). 
 78. 35 U.S.C. § 103(b)(1)(A) (2006). 
 79. E.g., U.S. Patent No. 141,072 (filed May 9, 1873). 
 80. E.g., Parke-Davis & Co v. H.K. Mulford & Co., 196 F. 496, 496 (2d Cir. 
1912) (considering whether purified adrenaline, having been previously 
discovered in animal suprarenal tissue, was patent eligible). 
 81. See, e.g., U.S. Patent No. 2,200,004 (filed Nov. 12, 1988); U.S. Patent 
No. 2,400,006 (filed Mar. 3, 1945). 
 82. See, e.g., Merck v. Mathieson, 253 F.2d 156, 164 (2d Cir. 1958); Parke-
Davis, 196 F. at 496. 
 83. Plant Patent Act of 1930, Pub. L. No. 245 (1930). 
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as it allowed inventors to patent living things that may have 
been, in a sense, invented by nature.84  In 1954, Congress 
amended the Plant Patent Act to separate the plant patent 
provisions from the original patent provisions and added more 
stringent requirements that the plants be new and distinct.85 
In 1970 Congress passed the Plant Variety Protection Act, 
which entrusted the Secretary of Agriculture to ensure plants 
are examined for protectability86 and established a plant 
variety protection board to oversee appeals  of an examiner’s 
decision not to protect a plant.87 Further, the Act extended the 
patent eligibility to sexually-reproducing plants, eliminating 
the requirement that inventors must have asexually 
reproduced the plant.88 
The USPTO and Supreme Court have since extended 
patent eligibility to non-plant organisms, including bacteria 
and the process of producing bacteria.89 However, when the 
“invention” for which an inventor is seeking protection is an 
organism or group of organisms,  an exception to patent 
eligibility may apply, and the inventor must not simply be 
attempting to patent a pure product of nature.90 To overcome 
this presumption, an inventor must demonstrate that the 
product of nature has become a new and distinctive article with 
new characteristics and/or a new use.91 Further, the 
presumption cannot be overcome by combining different groups 
of organisms, unlike patents on non-natural inventions.92 
There is some suggestion that this rule applies to purifications 
of substances found in nature as well.93 
 84. A plant that is created artificially and is not known in nature may be 
eligible for patent. See id. However, a patented plant may still exist in nature, 
albeit undiscovered. 
 85. Pub. L. No. 775, 68 Stat. 1190 (1954). 
 86. Plant Variety Protection Act, Pub. L. No. 577, 84 Stat. 1542 (codified 
at 7 U.S.C. §§ 2321–72, 2401–504, 2531–83). 
 87. Pub. L. 91–577, § 7, 84 Stat. 1543 (1970) (codified at 7 U.S.C. § 
2327(b)(2)). 
 88. Pub. L. 91–577, § 42, 84 Stat. 1547 (1970) (codified at 7 U.S.C. § 2402). 
 89. Diamond v. Chakrabarty, 447 U.S. 303, 310–11 (1980). It is worthy of 
note that the Plant Variety Protection Act specifically excluded bacteria from 
patent eligibility. Id. 
 90. Funk Bros. Seed Co. v. Kalo Inoculant Co. (Funk Bros.), 333 U.S. 127, 
130 (1948). 
 91. Anheuser-Busch Brewing Ass’n v. United States, 207 U.S. 556, 562 
(1908). 
 92. Funk Bros., 333 U.S. at 131–32. 
 93. See In re Merz, 97 F.2d 599, 601 (C.C.P.A. 1938) 
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This same concept has been applied to method/process 
patents as well. A natural process or law of nature is patent 
eligible, but only if, when the process is considered as a whole, 
the patent is attempting to gain protection for the application 
of the law, rather than the law itself.94 When the formula is 
applied to perform a function that patent law was developed to 
protect, the process should be given more leniency.95 This 
factor has led to some confusion in differentiating between 
patenting the application of a law of nature and patenting a 
fleshed-out abstract idea.96 
To summarize, the machine-or-transformation test 
required that all method/process patent eligible inventions 
must either be applied as some part of a machine or must be 
applied in a way that transforms something.97 But the 
machine-or-transformation test has been rejected as the sole 
test to determine patent eligibility of a process; instead, the 
proper test is whether the process amounts to an abstract 
idea.98 Unfortunately, no explicit definition or test for what 
constitutes an abstract idea has been provided.99 
Yet another layer of uncertainty has recently arisen in 
patent law: patenting human genes. Whether human genes fall 
into the category of a simple product of nature100 or something 
sufficiently transformed to be patent eligible101 is unclear. In 
its 2001 Utility Examination Guidelines, the USPTO 
consistently confirmed that genes were patent eligible subject 
matter.102 The USPTO suggests that a strand of DNA will be 
 94. Diamond v. Diehr, 450 U.S. 175, 187 (1981). 
 95. Id. at 192. 
 96. Compare Diehr, 450 U.S. at 192 (holding that an application for a 
mathematical formula to an end in furtherance of the purposes of patent law 
is patent eligible) and AT&T v. Excel Corp. 172 F.3d 1352, 1357 (Fed. Cir. 
1999) (holding that, for patent eligibility, a mathematical formula must be 
applied in a manner that creates a tangible result) with Parker v. Flook, 437 
U.S. 584, 595 n.18 (suggesting that the application of an improved method of 
calculation, even when supporting a specific end use, is not patent eligible). 
 97. E.g., In re Bilski, 545 F.3d 943, 956 (Fed. Cir. 2008). 
 98. Bilski v. Kappos, 130 S. Ct. 3218, 3231 (2010). 
 99. Id. 
 100. See, e.g., American Fruit Growers v. Brogdex Co., 283 U.S. 1, 11–12 
(1931) (finding a process not patentable because it was a simple product of 
nature). 
 101. Diamond v. Chakrabarty, 447 U.S. 303, 309–10 (1980). 
 102. UNITED STATES PATENT AND TRADEMARK OFFICE, DEP’T OF 
COMMERCE, RIN 0651-AB09, UTILITY EXAMINATION GUIDELINES passim 
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patentable when: (1) it has been isolated from its natural 
environment, (2) it has been purified, and (3) it meets the 
statutory requirements for patentability.103 The USPTO 
emphasizes the nonobviousness and utility requirements of the 
patent statute,104 and also clarifies that isolated genes, 
whether excised from a person’s cells or synthesized in a lab, 
are patentable because they vary so greatly from their natural 
forms.105 
The issue of patenting genes has also been brought to the 
Court of Appeals for the Federal Circuit, which has historically 
upheld gene patents. In 1995, the court held that a patent on a 
gene could not be invalidated solely because the method by 
which the gene was sequenced was a commonly exercised 
principle.106 The court was not convinced by the fact that the 
method used to discover the gene sequence was “obvious to try” 
because one of ordinary skill in the art, when trying the 
method, would have very little chance of contemplating the 
result.107 The court delivered a similar decision in 1993, which 
clarified that the obviousness of the method by which a patent 
holder discovered the compositions of DNA was not at issue in 
the case.108 The patent holder did not claim the method of 
discovery, but only the compositions, and because the 
compositions were not at all obvious, the patent could not be 
invalidated on grounds of obviousness.109 However, in 2007 the 
Supreme Court questioned these cases, and, in reinstating the 
obvious-to-try analysis, held that an invention will be 
considered obvious to try if “there is a design need or market 
pressure to solve a problem and there are a finite number of 
identified, predictable solutions.”110 The Court concluded that 
an invention found obvious to try can preclude patentability for 
§ 103 purposes.111 The Federal Circuit embraced the obvious-
to-try test in the recent genetic case, In re Kubin, holding that a 
(2001). 
 103. Id. at 1093. 
 104. Id. at 1093–95. 
 105. Id. at 1093. 
 106. In re Deuel, 51 F.3d 1552, 1557–59 (Fed. Cir. 1995). 
 107. Id. 
 108. In re Bell, 991 F.2d 781, 785 (Fed. Cir. 1993). 
 109. Id. 
 110. KSR Intern. Co. v. Teleflex Inc., 550 U.S. 398, 421 (2007). 
 111. See id. (suggesting that finding a combination of elements making up 
an invention obvious-to-try may show that it is obvious under the statute). 
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finding of obvious-to-try will equal a finding of obviousness in 
almost all cases.112 While the specific question with which the 
court is faced in Myriad may be one of first impression, 
patenting of genes and even of life is far from a new subject. 
D. COMMENT PREVIEW 
The purpose of this Comment is to explore the underlying 
issues of the suit between the Association for Molecular 
Pathology and Myriad Genetics, and to determine the proper 
course of action for the Court of Appeals for the Federal Circuit 
and the Supreme Court, should the case continue to that level. 
Analysis of such a complex issue will require an incorporation 
of public policy and legal issues. To that end, this Comment will 
first present in greater detail the disputed patents and issues of 
Myriad at its current state. The next section will examine the 
public policy ramifications of invalidating or validating the 
seven patents at issue, including a consideration of the effects 
on all present and potential future genetic patents. This 
Comment will then analyze the legal arguments and 
consequences of each possible decision. Finally, this Comment 
will conclude with a summary of the analysis section and a 
final suggestion on the overall best course of action. 
III. CASE DESCRIPTION 
In 1997, Myriad was granted a patent on a human gene, 
BRCA1, which directs the development of a protein in both men 
and women that is linked to hereditary breast cancer.113 
Between 1998 and 2000 Myriad was granted six more 
patents114 relating to both the BRCA1 and BRCA2 genes and 
the methods of using them to diagnose hereditary breast 
cancer.115 Myriad has been the sole provider offering the 
 112. In re Kubin, 561 F.3d 1351, 1359 (Fed. Cir. 2009) (holding that if an 
inventor merely guesses at the proper use of a large pool of prior art by 
“throw[ing] metaphorical darts at a board filled with prior art possibilities,” or 
if all that was obvious to try was “to explore a new technology or general 
approach” and “prior art gave only general guidance,” being obvious to try 
would not lead to a finding of obviousness. See id. (quoting In re O’Farrell, 853 
F.2d 894, 903 (Fed. Cir. 1988)). 
 113. Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office 
(Myriad), 702 F. Supp. 2d 181, 189, 201 (S.D.N.Y. 2010). 
 114. The University of Utah Research Foundation is a joint holder of these 
patents. Id. at 189–90. 
 115. Id. 
 2011] MEDICINE AND PATENT LAW 825 
                                                          
diagnostic tests ever since, because its patents give it a 
monopoly on the underlying methods. Plaintiffs,116 unhappy 
with (1) the costs of Myriad’s diagnostic testing, (2) their 
inability to perform competitive diagnostic testing, or (3) 
Myriad’s potential ability to prevent outside research on 
BRCA1 and BRCA2, brought an action against the USPTO and 
Myriad117 in the United States District Court for the Southern 
District of New York to invalidate the patents. The district 
court case was heard and decided by Judge Robert Sweet.118 
The plaintiffs moved for summary judgment, arguing that 
the disputed claims covered only products of nature, laws of 
nature/natural phenomena, and abstract ideas.119 Myriad 
cross-moved for summary judgment, and the USPTO moved for 
judgment on the pleadings.120 The court granted the plaintiffs’ 
motion against Myriad, granted the USPTO’s motion, and 
denied Myriad’s cross-motion.121 
The opinion discussed three accepted exceptions to the 
general patentability of new and useful inventions: the law of 
nature exception, the physical phenomena exception, and the 
abstract idea exception.122 It then addressed the composition of 
matter claims and method claims in turn, citing different 
support for patent ineligibility for each category.123 The opinion 
focused on a product of nature exception to the general patent 
eligible status given to compositions of matter.124 This 
exception, according to the opinion, establishes that 
compositions of matter are not patentable if those compositions 
of matter are merely products of nature that have not been 
changed to the point of being fundamentally a new product.125 
 116. An exhaustive list of all plaintiffs would be, appropriately, exhausting 
to list here. Together, there are twenty plaintiffs, encompassing four research 
groups, eight doctors and scientists, two health action groups, and six women 
diagnosed with breast cancer. Id. at 186–89. 
 117. The University of Utah Research Foundation was also listed as a 
defendant, as it had partial ownership of the patents-in-suit. Id. at 189–90. 
 118. Id. at 183. 
 119. Id. at 184. 
 120. Id. at 184–85. 
 121. Id. at 238. The claims against the USPTO were dismissed due to the 
doctrine of constitutional avoidance. This doctrine will not be discussed by this 
Comment. 
 122. Id. at 219 n. 40. 
 123. Id. at 220–37. 
 124. Id. at 222–27. 
 125. Id. at 222. 
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For this exception, the opinion relies on three cases:126 
American Fruit Growers, Inc. v. Brogdex Co.,127 Funk Bros. 
Seed Co. v. Kalo Inoculant Co.,128 and Diamond v. 
Chakrabarty.129 This test establishes that an invention may 
defeat the product of nature exemption if the invention has 
been changed to such an extent as to have a “distinctive name, 
character, [and] use” from the product of nature.130 
The opinion concludes that Myriad’s composition of matter 
claims do not pass the product of nature test, as the claimed 
DNA is not markedly different than the natural DNA.131 In 
arriving at this conclusion, it suggests that DNA should be 
judged differently than many chemical compounds because of 
the importance of the information-storing capacities of DNA.132 
That the claimed DNA does not contain non-coding regions of 
the strand, is not attached to other genes on a chromosome, 
and is not located among other components of a cell 
environment are irrelevant. That the information encoded 
remains unchanged between the claimed DNA and the natural 
DNA is enough to show that the claimed DNA is not markedly 
different from the natural DNA.133 The opinion notes that the 
claimed DNA would, in fact, be worthless if the information 
encoded were not exactly the same as natural DNA.134 Further, 
it suggests that many of Myriad’s claims could be invalidated 
because they are broad enough to encompass natural DNA as 
well as synthesized DNA, which is, by definition, not markedly 
different from a product of nature.135 Even the claims for 
cDNA, it suggests, are not markedly different from products of 
nature, because cells have the means to produce cDNA from 
native DNA, and therefore cDNA may exist in the cell.136 
Myriad’s method claims are also held to be invalid.137 The 
 126. Id. at 222–23. 
 127. American Fruit Growers v. Brogdex Co., 283 U.S. 1 (1931). 
 128. Funk Bros. Seed Co. v. Kalo Inoculant Co. (Funk Bros.), 333 U.S. 127 
(1948). 
 129. Diamond v. Chakrabarty, 447 U.S. 303 (1980). 
 130. Myriad, 702 F. Supp. 2d at 223 
 131. Id. at 220. 
 132. Id. at 228. 
 133. Id. at 229. 
 134. Id. at 231. 
 135. Id. at 230. 
 136. Id. 
 137. Id. at 232–37. 
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finding is based not on any of the three discussed exceptions, 
but rather on the “machine or transformation” test articulated 
by the Federal Circuit in In re Bilski.138 According to the 
machine or transformation test, a claim for a method is invalid 
if it is not connected to a machine, or does not transform an 
article.139  Myriad’s claims do not teach a method that is 
connected to a machine and the transformation argued by 
Myriad is insufficient.140 The opinion states that Myriad’s 
claims are too broad because they only use general terms such 
as “data gathering” and “comparing.”141 Further, drawing of a 
patient’s blood and isolating his or her DNA sample are not 
transformative enough because it is simply collecting a sample 
and preparing it for data-gathering.142 The transformation 
must be essential to the claimed process, and drawing blood 
and isolating the DNA are not the focus of Myriad’s claimed 
method—the focus is in comparing the two samples.143 
Comparing the two samples is simply an application of the 
scientific method, which is neither transformative nor novel.144 
The court did not address whether the composition-of-matter or 
diagnostic-method patents were patentable under § 102 for 
novelty and § 103 for nonobviousness.145 
Myriad’s composition-of-matter claims were held to be 
patent ineligible because they were products of nature. 
Myriad’s method claims were also held to be patent ineligible 
because they were not tied to a machine or transformation 
process. The district court opinion was filed on March 29, 2010, 
invalidating Myriad’s patents.146 Myriad filed a notice of appeal 
to the Court of Appeals for the Federal Circuit on June 16, 
2010, seeking reversal of the decision.147 
 138. In re Bilski, 545 F.3d 943 (Fed. Cir. 2008), modified, Bilski v. Kappos, 
130 S. Ct. 3218, 3226 (2010). 
 139. Myriad, 702 F. Supp. 2d at 233. 
 140. Id. 
 141. Id. at 234, 236. 
 142. Id. at 236. 
 143. Id. 
 144. Id. at 237. 
 145. Id. at 220 (noting that the sole purpose of the court was to determine 
whether Myriad’s inventions fell under the product of nature exception). 
 146. Id. at 181. 
 147. Notice of Appeal for Appellant Myriad at 1, Ass’n for Molecular 
Pathology v. Myriad Genetics Inc., No. 2010-1406 (Fed. Cir. filed June 16, 
2010). The USPTO, on the other hand, did not appeal, as the court dismissed 
the claims against it. Myriad, 702 F. Supp. 2d at 237–38. 
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IV. ANALYSIS 
This section will present precedents of finding gene patents 
eligible and explain how the Myriad opinion improperly applied 
Chakrabarty, Funk Bros. and the now-questionable In re Bilski 
and was therefore insufficient to reverse the USPTO’s decision 
and find that genes are patent ineligible. This section will then 
explain the need for gene patent eligibility from a public policy 
viewpoint.148 Finally, it will explore the § 102 novelty and § 103 
obviousness obstacles genetic diagnostic methods are likely to 
face before being granted patent status. 
A. MYRIAD’S COMPOSITION-OF-MATTER CLAIMS ARE PATENT 
ELIGIBLE 
This section will show that the court’s analysis fails to 
invalidate Myriad’s composition of matter patents. First, 
Myriad’s composition of matter patents do not fall under the 
product of nature exception. Second, they are more than 
purifications of natural mixtures. Third, Funk Bros., arguably 
the opinion’s strongest support, does not apply to this action. 
Finally, deference to Congress, the USPTO, and other courts 
strongly supports a finding of patent eligibility. 
1. The Scope of § 101 
Section 101, addressing what inventions are eligible to be 
considered for patents, was written to apply broadly.149 The 
1793 Act is said to have been authored by Thomas Jefferson,150 
who instilled in it his belief that “ingenuity should receive a 
liberal encouragement.”151 Though the Act has been amended 
 148. This Comment approaches legal analysis first, for if patenting genes is 
found to be clearly foreclosed by law, public policy is moot.  See Dir., Office of 
Workers’ Comp. Programs v. Newport News Shipbuilding & Dry Dock Co., 514 
U.S. 122, 129 (1995) (holding that, absent clear language in the statute in 
question, workers rights could not be brought to court by the secretary of labor 
even though public policy greatly favored it); Diamond v. Chakrabarty, 447 
U.S. 303, 317–18 (1980) (holding that the court is neither equipped nor 
authorized to second-guess Congress’ determinations of patent eligibility 
based on public policy concerns). 
 149. 35 U.S.C. § 101 (2006) (establishing that “any new and useful. . . 
composition of matter. . . or any new and useful improvement thereof” may be 
patented subject to other restrictions of the act) (emphasis added). 
 150. Chakrabarty, 447 U.S. at 308–09. 
 151. Thomas Jefferson in 5 WRITINGS OF THOMAS JEFFERSON 75–76 
(Washington ed. 1871). 
 2011] MEDICINE AND PATENT LAW 829 
                                                          
multiple times, Jefferson’s broad language has never been 
restricted.152 In fact, accompanying the latest amendment in 
the 1952 Act, Congressional committee reports explicitly state 
that “anything under the sun that is made by man” qualifies for 
patent eligibility under § 101.153 The courts have concluded 
that advanced technologies that Congress would have had no 
way of anticipating when the act was written are not patent 
ineligible per se.154 Indeed, the Supreme Court has held that it 
cannot read limitations into statutes that were not intended by 
Congress.155 However, the Supreme Court has also cautioned 
that courts should use extreme prudence when “expanding” 
patent eligibility to those areas.156 As guidance, the Supreme 
Court has established three general exceptions to the 
presumption of patent eligibility: laws of nature, physical 
phenomena, and abstract ideas.157 
2. The Product-of-Nature Exception is Valid 
The Myriad respondents successfully argued that human 
genes, when isolated from surrounding DNA and other cellular 
components, are not patent eligible because they fall under the 
product-of-nature exception.158 Myriad argues, however, that 
this “product of nature’ exception on which the decision relies is 
not one of the three exceptions described in Chakrabarty. 
Chakrabarty does not mention a “product of nature” exception, 
but only “laws of nature.”159 The Myriad opinion describes the 
“product of nature” exception as a general combination of “the 
law[] of nature, natural phenomenon, and abstract idea[]” 
exceptions cited in Chakrabarty,160 and one of the examples the 
Court used in Chakrabarty to clarify the three exceptions fits 
Judge Sweet’s definition of a product of nature.161 Myriad 
 152. Chakrabarty, 447 U.S. at 309. 
 153. S. REP. NO. 82-1979 at 5 (1952). While this statement may be too 
overbroad to be read literally, it certainly supports a broad construction o the 
act. 
 154. Chakrabarty, 447 U.S. at 316. 
 155. United States v. Dubilier Condenser Corp. 289 U.S. 178, 199 (1933). 
 156. Parker v. Flook, 487 U.S. 584, 596 (1978). 
 157. Chakrabarty, 447 U.S. at 309. 
 158. Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office 
(Myriad), 702 F. Supp. 2d 181, 184, 222, 228 (S.D.N.Y. 2010). 
 159. 447 U.S. at 309. 
 160. Myriad, 702 F. Supp. 2d at 220. 
 161. Chakrabarty describes a hypothetical new mineral discovered in the 
earth as patent ineligible under the three exceptions. 447 U.S. at 309. 
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argues that the products of nature test improperly limits the 
statute beyond congressional intent.162 Myriad itself admits 
that the exceptions set out in Chakrabarty were meant not to 
limit the statute but to provide guidance for the “new and 
useful” determination of § 101.163 This type of guidance is 
precisely the purpose of the courts.164 Myriad also suggests 
that such a sweeping exception in patent law would frustrate 
the patent statute, but does not give support for the district 
court or court of appeals to overturn a holding of the Supreme 
Court.165 Myriad has not established that the district court 
misunderstood the underlying exceptions expressed by the 
Supreme Court in Chakrabarty.  Myriad’s argument against 
the “product of nature” exception, without more, is merely 
semantic. 
3. Myriad’s Genes Do Not Fall Under the Product of Nature 
Exception. 
Myriad’s stronger argument is that which it presented to 
the district court: that its patented genes have been sufficiently 
altered so as to not fall under any of the three exceptions.166 
Even if natural DNA is generally analogous to a hypothetical—
newly discovered mineral, as described in dicta as patent 
ineligible by Chakrabarty167—Myriad argues that its claimed 
DNA is not specifically analogous, because it is isolated from its 
cellular surroundings and is devoid of introns and any DNA 
associated proteins, it is purified.168 
The Myriad opinion’s analysis of the exceptions in 
Chakrabarty focused on whether Myriad’s claimed DNA meets 
“[the] requirement that an invention possesses ‘markedly 
 162. Brief for the Appellants at 1, Ass’n for Molecular Pathology v. Myriad 
Genetics, Inc., No. 2010-1406 (Fed. Cir. filed June 16, 2010). 
 163. Id. at 33. 
 164. Cf. Marbury v. Madison, 5 U.S. (1 Cranch) 137, 147 (1803) (holding 
that the U.S. Supreme Court has jurisdiction to interpret laws passed by 
Congress). 
 165. Brief for the Appellants, supra note 162 at 46. 
 166. Myriad, 702 F. Supp. 2d at 224. 
 167. See supra note 161. This comment, for argument’s sake, will assume 
that natural DNA, extracted in a pure chromosomal form, is directly 
analogous to  the hypothetical mineral described in the Court’s analysis in 
Chakrabarty. 
 168. Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office 
(Myriad), 702 F. Supp. 2d 181, 224 (S.D.N.Y. 2010). 
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different characteristics’ [than the natural analog].”169 Myriad 
argues that Chakrabarty did not establish the “markedly 
different characteristics” analysis as a test.170 Instead, Myriad 
suggests, the Court intended the test to be whether the claimed 
invention has “distinctive name, character, and use.”171 Myriad 
was correct that Chakrabarty did not establish the “markedly 
different characteristics” analysis as a test for determining 
whether a claimed invention is sufficiently altered to avoid the 
three exceptions. But Chakrabarty did not indicate that the 
“distinctive name, character, and use” analysis was to be the 
sole test; its discussion on the matter was quite specific to the 
facts of that case and did not establish a particular test.172 
Therefore, a proper analysis would treat the “markedly 
different characteristics” analysis, the “distinctive name, 
character, and use” analysis, and all other reasoning expressed 
by Chakrabarty equally. 
When determining whether the claimed invention fits 
under one of the three exceptions, the Chakrabarty court posed 
the question of whether the claim is to “a hitherto unknown 
natural phenomenon” or a “nonnaturally occurring 
manufacture or composition of matter.”173 The court mentioned 
the following criteria as guidance: (1) whether the claim is to “a 
product of human ingenuity having a distinctive name, 
characteristic, and use,”174 (2) whether the claim is to 
something “with markedly different characteristics from any 
found in nature and one having the potential for significant 
utility,” and (3) whether the claim is to “nature’s own 
handiwork or [the patentee’s].”175 While Chakrabarty did not 
establish any of these criteria as an exclusive test for patent 
eligibility, because Myriad’s composition-of-matter claims are 
supported by all three characteristics, the Chakrabarty 
analysis is sufficient. 
The opinion suggests that Myriad’s composition claims 
point to natural phenomena that occur naturally absent human 
intervention, because both Myriad’s claimed BRCA1 and 
 169. Id. at 223 (quoting Diamond v. Chakrabarty, 447 U.S. 303, 310 
(1980)). 
 170. Brief for Appellants, supra note 162, at 41–42. 
 171. Id. at 42 (quoting Chakrabarty, 447 U.S. at 309–10). 
 172. See Chakrabarty, 447 U.S. 309–10. 
 173. Id. at 309. 
 174. Id. at 309–10 (quotation omitted). 
 175. Id. at 310. 
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BRCA2 genes and natural BRCA1 and BRCA2 genes have the 
same informational encoding capacity and purpose.176 As 
Myriad notes, the court erred in focusing on such a narrow 
aspect of Myriad’s claims,177 because claims must be considered 
as a whole when determining patent eligibility.178 Myriad 
essentially argues that their inventions were held patent 
ineligible because of general genetic concept, when they should 
have been held patent eligible because of the changes Myriad 
made to the DNA.179 “[I]t is inappropriate to dissect the claims 
into old and new elements and then to ignore the presence of 
the old elements in the analysis.”180 When Myriad’s claims are 
viewed more thoroughly, they are patent eligible. 
i. Myriad’s Claims Are the Product of Human Ingenuity 
Having Distinctive Characteristics and Uses 
Myriad admits that its claimed genes and the natural 
genes are codes for the same exact proteins.181 This concession 
is not surprising, because the entire purpose of sequencing and 
isolating the BRCA1 and BRCA2 genes was to discover the 
cancer-related proteins for which they code.182 However, this 
code serves different purposes in the claimed and in natural 
DNA. The purpose of the sequence of genes in natural DNA is 
to make the production of proteins possible.183 The purpose of 
the sequence of genes in Myriad’s claimed isolated DNA is to 
identify mutations in BRCA1 and BRCA2 genes.184 The 
structural differences between the two types of DNA serve this 
 176. Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office 
(Myriad), 702 F. Supp. 2d 181, 229 (S.D.N.Y. 2010). 
 177. Brief for the Appellants, supra note 162, at 51. 
 178. Diamond v. Diehr, 450 U.S. 175, 188 (1981). 
 179. Brief for the Appellants, supra note 162, at 51. 
 180. Id. 
 181. Myriad, 702 F. Supp. 2d at 231. 
 182. Id. at 201. 
 183. See SOLOMON, ET AL., supra note 2 at 261, 278. While Myriad’s 
isolated DNA do not serve this purpose, some isolated DNAs could be useful 
for laboratory protein production. In this case, the use would still be different 
from that of natural DNA. Natural DNA produces only small amounts of 
protein for use in the body, while isolated DNA could be used to produce 
extremely large amounts of protein for sale or other purposes. Brief of Amici 
Curiae Rosetta Genomics, Ltd., et al. as Amici Curiae supporting Appellants, 
at 23, Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 702 (No. 2010-
1406) (Fed. Cir. filed June 16, 2010). 
 184. Myriad, 702 F. Supp. 2d at 203. 
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difference in purpose: as Myriad puts it, natural “DNA is 
useless for the diagnostic and detection applications for which 
the isolated molecules may be utilized.”185 To begin with, 
isolated DNA is not found in chromosomal form, and thus it is 
never coiled, twisted, or surrounded by proteins that make it 
difficult or impossible to compare the sequence of one gene with 
that of another.186 That the claimed DNA is isolated suggests 
that it is also separated from the thousands of other genes on 
the chromosome, making the DNA far less unwieldy.187 
Further, isolated DNA is without extra sequences unimportant 
to gene comparison, such as sequences that serve to regulate 
cellular processes and noncoding introns.188 
These distinctions between native and isolated DNA are 
not a product of nature’s efforts. Indeed, the Myriad court 
admitted that the differences are a direct result of Myriad’s 
effort and ingenuity.189 This is necessarily so, because the 
human body can neither isolate DNA nor cDNA, such that 
neither can regularly occur in nature and both are the result of 
genetic manipulation.190 The changes Myriad has made to the 
DNA “permit the direct yoking of natural processes for 
mankind’s purposes.”191 Clearly, Myriad’s claimed DNA is the 
product of human ingenuity having distinctive characteristics, 
uses, and (if the scientific community so chooses) names from 
natural DNA.192 
ii. The Distinctions Between Myriad’s DNA and Natural DNA 
are Marked, and Create the Potential for Significant Utility193 
Chakrabarty gave no guidance for determining if a claimed 
 185. Brief for the Appellants, supra note 162, at 51. 
 186. Myriad, 702 F. Supp. 2d at 195–96. 
 187. See Rosetta Genomics, supra note 183 at 23 (describing chromosomes 
as large structures with numerous genes and DNA sequences). 
 188. Id. at 24. 
 189. Myriad, 702 F. Supp. 2d at 202. 
 190. Rosetta Genomics, supra note 183 at 22–23; Brief for the United 
States as Amicus Curiae in Support of Neither Party at 15, Ass’n for 
Molecular Pathology v. Myriad Genetics, Inc., No. 2010-1406 (Fed. Cir. briefs 
submitted Oct. 22, 2010). The U.S. Department of Justice notes in its amicus 
brief that cDNAs do sometimes occur in nature, in viruses, for example, but 
not in humans. 
 191. See Brief for the United States, supra note 190, at 16. 
 192. See Rosetta Genomics, supra note 183, at 22–23. 
 193. The utility for diagnostic tests, made possible by isolated DNA is 
discussed in the public policy section below. See infra Part IV.C.. 
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invention is “markedly different.”194 However, the way 
Chakrabarty made the determination is instructive. The 
patentee had invented a biologically engineered bacterium by 
inserting new DNA sequences into the bacterium’s natural 
DNA.195 The claimed bacterium, as a result of the patentee’s 
engineering, was able to degrade oil more efficiently, and thus 
was useful in treating oil spills.196 Previously, multiple bacteria 
were required to degrade oil, but the claimed bacterium was 
able to do the same work alone.197 Therefore, in Chakrabarty, 
an organism’s DNA was altered to allow it to perform a task 
more efficiently. The inventive difference between the invention 
and its natural counterpart was the change in DNA. Similarly, 
the inventive difference (among others) between Myriad’s 
invention and its natural counterpart is a change in DNA.198 
While the sequences encoding the gene remain in both Myriad’s 
invention and its natural counterpart, the amount of DNA and 
other substances removed cause a marked difference.199 
Further, the operative difference between the Chakrabarty 
invention and its natural counterpart is an improvement in 
performance.200 However, the operative difference between 
Myriad’s invention and its natural counterpart is an entirely 
new use that would have been impossible without the 
invention.201 Myriad’s is the only test available to diagnose 
hereditary breast cancer.202 Therefore, there are marked 
operative differences between Myriad’s DNA and natural DNA. 
iii. Myriad’s Claims are to Myriad’s Handiwork, Not Nature’s 
As discussed, the new use resulting from Myriad’s claimed 
invention developed from Myriad’s ingenuity.203 For example, 
 194. Diamond v. Chakrabarty, 447 U.S. 303, 310 (1980). 
 195. Id. at 305. 
 196. Id. at 305 n.2. 
 197. Id. 
 198. Brief for the Appellants, supra note 162 at 50–51. The difference 
between this case and Chakrabarty is that here DNA was removed, instead of 
added. 
 199. See supra notes 185–188 and accompanying text. 
 200. Chakrabarty, 447 U.S. at 305 n.2. 
 201. Brief for the Appellants, supra note 162 at 50–51. 
 202. Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office 
(Myriad), 702 F. Supp. 2d 181, 206 (S.D.N.Y. 2010). 
 203. Id. at 202. 
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cDNA,  is not found naturally in humans204 and there is no 
natural method for isolation of DNA.205 Because the differences 
between Myriad’s invention and its natural counterpart result 
largely from the isolation of the DNA and its change to cDNA, 
the differences cannot be said to be nature’s handiwork.206 
Further, because these differences are the direct causes of the 
usefulness of Myriad’s claimed invention,207 it follows that the 
invention is not nature’s handiwork. 
The Myriad opinion mentions that at least one of Myriad’s 
claims can be read so broadly that it encompasses the DNA 
that it exists in the human body and that Myriad is therefore 
claiming nature’s handiwork.208 But this is not an appropriate 
reading of the claims. A patent’s claims must be read in light of 
all other claims, the specification, and the invention as a 
whole.209 Given that the clear purpose of Myriad’s invention is 
to diagnose likelihood of hereditary breast cancer and that 
natural DNA is useless to that end, it is nonsensical and 
against patent regulations to read any of Myriad’s claim in a 
way that would include natural DNA as it exists in humans.210 
4. Myriad’s Genes Are Not Patent Ineligible Because They Are 
Purifications of a Natural Substance 
Amici (notably, the United States Department of Justice) 
argue that genes cannot be patented as compositions of matter 
due to the longstanding exception to § 101 that purification of 
something unpatentable does not result in a patent eligible 
invention.211 In Cochrane, the patentee originally attempted to 
patent both a process for synthesizing a dye that was 
previously available only by extraction from a plant and the 
dye itself.212 The synthetic dye was found not patent eligible 
 204. See United States, supra note 190 at 15. 
 205. Rosetta Genomics, supra note 183 at 22. 
 206. See supra notes 189–191 and accompanying text. 
 207. See supra notes 184–186 and accompanying text. 
 208. Myriad, 702 F. Supp. 2d at 230. 
 209. See 37 C.F.R. § 1.104 (2009) (establishing that examination of a patent 
must be a thorough study of the whole application); 35 U.S.C. § 112 (2006) 
(establishing that the application’s specification provides context for the 
invention and manner of use of the invention); supra notes 178, 180 and 
accompanying text. 
 210. 37 C.F.R. § 1.104 (2010); supra notes 178, 180 and accompanying text. 
 211. Cochrane v. Badische Anilin & Soda Fabrik, 111 U.S. 293, 311–12 
(1884). 
 212. Id. 
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because it was not a new article.213 However, there is a 
longstanding exception to the purification exclusion: purified 
articles that differ from their previous counterparts not only  in 
degree of purity but also in kind adopt a new use are patent 
eligible.214 In re Merz invalidated a patent for a dye for the 
same reasons given in Cochrane,215 but noted in dicta that if 
the dye had been so much purer that it differed in kind and was 
useful in a new way from the previous dye, it would have been 
patentable.216 
It is undisputed that the isolation and purification of the 
BRCA1 and 2 genes from their natural environment has 
created articles different in kind from their natural 
counterparts.217 While genes purified to a lesser extent than 
Myriad’s genes may still be useful to produce proteins, they 
would be useless for diagnostic tests.218 Only Myriad’s genes, 
once purified, are useful for this application.219 Therefore, they 
fall under the “different in kind” exception, and are not patent 
ineligible because they are purifications. 
5. Myriad’s Genes Are Not Patent Ineligible Under Funk Bros. 
The Myriad opinion relied to a large extent on Funk Bros. 
to establish that Myriad’s genes are patent ineligible under § 
101.220 Funk Bros. held that combining three types of bacteria 
into a culture that efficiently allows plants to fix nitrogen from 
the atmosphere did not result in a patentable invention.221 
Because it was well known that these species of bacteria 
allowed plants to fix nitrogen and that certain species of the 
bacteria inhibited the fixing effects of other species, it was a 
clear next step to combine only bacteria that do not inhibit each 
other when composing plant additives.222 This analysis is 
 213. Id. 
 214. In re Merz, 97 F.2d 599, 601 (C.C.P.A. 1938). 
 215. Id. 
 216. Id. 
 217. See supra notes Part IV.A.3.i. 
 218. See supra notes Part IV.A.3.ii. 
 219. See supra notes Part IV.A.3.ii. 
 220. Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office 
(Myriad), 702 F. Supp. 2d 181, 232 (S.D.N.Y. 2010). 
 221. Funk Bros. Seed Co. v. Kalo Inoculant Co. (Funk Bros.), 333 U.S. 127, 
129–30, 131–32 (1948). 
 222. Id. 
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known today as the obviousness analysis from § 103.223 
However, Funk Bros. was decided just before the Patent Act of 
1952, when the obviousness rejection from Hotchkiss was so 
named and codified under § 103.224 Therefore, Funk Bros. is not 
applicable to modern cases of patent eligibility under § 101, but 
under § 103,225 and thus Myriad’s claims cannot be held to be 
patent ineligible under § 101 due to Funk Bros. Even if the 
obviousness standard applied to patent eligibility in this case, 
Myriad’s claims would still not be ineligible. 
6. Deference to USPTO Determination, Precedent, and 
Congressional Intent Support Patentability of Genes as 
Compositions of Matter 
The Supreme Court has deferred to the longstanding 
judgment of the patent office in its reading of statutes 
governing patent eligibility.226 Given the over 40,000 patents 
on genes issued by the USPTO—and the lack of any action to 
the contrary by Congress—a holding that genes are not patent-
eligible would violate the precedent of deference to the 
longstanding judgment of the USPTO.227 Further review of the 
precedents shows that the Federal Circuit, which, due to their 
expertise in the field, handles all appeals from the Board of 
Patent Appeals and Interferences,228 has a history of assuming 
 223. 35 U.S.C § 103 (2006). See also KSR Int’l Co. v. Teleflex Inc., 550 U.S. 
398, 406 (2007) (explaining the test for obviousness under § 103). 
 224. Funk Bros., 333 U.S. at 127; KSR, 550 U.S. at 406 (stating that the 
analysis and language from § 103 in the 1952 Patent Act establishing §§ 100–
03 was taken from Hotchkiss v. Greenwood); Hotchkiss v. Greenwood, 52 U.S. 
(11 How.) 248, 267 (1851). 
 225. Brief for Alnylam Pharmaceuticals, Inc. as Amicus Curiae Supporting 
Petitioners at 13-14, Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 
No. 2010-1406 (Fed. Cir. Oct. 22, 2010). 
 226. See, e.g., J.E.M. AG Supply v. Pioneer Hi-Bred Int’l, 534 U.S. 124, 
144–45 (2001) (holding that, because the USPTO had found multiple plant 
inventions patent eligible under § 101, and because Congress had not 
expressed disapproval of such findings, a holding against the USPTO’s 
judgment on patent eligibility would be improper). 
 227. Rosetta Genomics, supra note 183, at 14; Genomic Research and 
Accessibility Act, H.R. 977, 110th Cong. (2007) [hereinafter GRAA] (this bill 
never became law), available at 
http://www.govtrack.us/congress/billtext.xpd?bill=h110-977. 
 228. Court Jurisdiction, UNITED STATES COURT OF APPEALS FOR THE 
FEDERAL CIRCUIT, 
http://www.cafc.uscourts.gov/index.php?option=com_content&view=article&id
=144&Itemid=27 (last visited Nov. 22, 2010). Given the fact that this court 
was formed from the United States Court of Customs and Patent Appeals and 
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genes to be patent eligible.229 Finally, the fact that Congress 
explicitly refused to bar gene patent eligibility under § 101 in 
the Genomic Research and Accessibility Act,230 especially in 
light of growing controversy on the issue, demonstrates the 
congressional intent that genes remain eligible for patenting. 
B. MYRIAD’S METHOD CLAIMS ARE PATENT ELIGIBLE UNDER  § 
101 
1. The “Machine-or-Transformation” Test Is No Longer 
Dispositive 
The Myriad opinion’s invalidation of Myriad’s method 
claims relied heavily on the Federal Circuit’s decision in In re 
Bilski.231 But the district court’s view that Myriad’s method is 
not tied to a particular machine or apparatus and does not 
perform sufficient transformation is no longer dispositive since 
the Supreme Court’s disapproval of In re Bilski, on the ground 
that the “machine-or-transformation” test was not meant to be 
a binding test.232 Instead, method patents which otherwise 
comply with statutory provisions are patent eligible unless they 
are merely abstract ideas.233 
After the Supreme Court’s Bilski decision, the machine-or-
transformation analysis remains important as a “clue” in 
determining patent eligibility.234 Myriad’s method claims are 
made more patent eligible, rather than less, by this analysis. 
There are multiple steps that a court could identify as 
transformative; a patient’s blood must first be treated and the 
DNA from the blood must be isolated and sequenced.235 This is 
especially determinative, as the Federal Circuit has recently 
held similar treatment of blood to be transformative in 
Prometheus Laboratories, Inc. v. Mayo Collaborative 
the deference the Supreme Court gives to the expertise of the Board of Patent 
Appeals and Interferences, this court can be assumed to have some expertise 
in patents. See J.E.M. 534 U.S. at 144–45. 
 229. See, e.g., Amgen, Inc. v. Chugai Pharm. Co., 927 F.2d 1200, 1219 (Fed. 
Cir. 1991). 
 230. See GRAA, supra note 227. 
 231. Supra notes 137–144 and accompanying text. 
 232. Bilski v. Kappos, 130 S. Ct. 3218, 3226 (2010). 
 233. See id. at 3229–30. 
 234. Id. at 3227. 
 235. Brief for the Appellants, supra note 162 at 55. 
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Services.236 The machine-or-transformation analysis, therefore, 
strengthens the patent eligibility of Myriad’s method claims. 
2. Myriad’s Method Claims Are Not Abstract Ideas 
The Myriad opinion suggests that Myriad’s method claims 
are patent ineligible because they are related not to any 
particular method of analysis, but instead to the mental 
process of “comparing” sequences.237 However, Myriad’s 
method claims represent far more intricate processes than 
simply looking at a list of nucleotides side-by-side. To begin, 
isolating the correct sequences of a person’s DNA requires 
several non-abstract steps.238 Further, any differences between 
a person’s DNA and Myriad’s gene will need to be examined to 
determine whether those mutations are of any effect. Because 
this requires extensive analysis,239 Myriad had to develop 
several tests to identify different types of mutations.240 
Myriad’s tests are far from abstract ideas and are therefore 
patent eligible. 
C. POLICY RAMIFICATIONS OF INVALIDATING GENE PATENTS 
The Myriad opinion’s sudden invalidation of patents on 
human genes, if supported by higher courts and the USPTO, 
will have tremendous consequences,241 and it has already 
unsettled much of the patent community.242 To begin, the 
 236. Prometheus Labs., Inc. v. Mayo Collaborative Servs., 628 F.3d 1347, 
1356 (2010). 
 237. Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office 
(Myriad), 702 F. Supp. 2d 181, 233 (S.D.N.Y. 2010). 
 238. Brief for the Appellants, supra note 162, at 55. 
 239. See Myriad, 702 F. Supp. 2d at 195 (explaining that different types of 
mutations in a person’s DNA will have different effects); id. at 195 n.5 
(explaining that extensive analysis is required to determine what effect each 
mutation will have); supra notes 42–44 and accompanying text (explaining 
that many mutations will have no effect). 
 240. Myriad, 702 F. Supp. 2d at 203. 
 241. Dennis Crouch referred to the decision as “a powerful move.” Dennis 
Crouch, Court: Essentially All Gene Patents Are Invalid, PATENTLY-O (Mar. 
30, 2010, 7:17 AM), http://www.patentlyo.com/patent/2010/03/court-
essentially-all-gene-patents-are-invalid.html. The title of this blog entry 
emphasizes the far-reaching potential this decision could have. 
 242. Paul M. Janicke, Guest Post: An Interesting Preview of Myriad?, 
PATENTLY-O (Sept. 26, 2010, 10:29 PM), 
http://www.patentlyo.com/patent/2010/09/guest-post-an-interesting-preview-
of-myriad.html. 
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USPTO has granted patents to over 40,000 genes,243 over 
ninety-nine percent of which have never been challenged. 
Moreover, only a fraction of the remaining one percent were 
challenged because of their patent eligibility or ineligibility.244 
The purpose of patent law is to “promote the Progress of 
Science and the useful Arts.”245 The patent system promotes 
science by giving inventors an incentive to develop marketable 
inventions and technologies.246 However, the public at large is 
benefitted greatly by the patent system as well for at least two 
reasons: (1) many useful inventions that are patented are 
marketed and sold to consumers, who benefit from the 
invention’s availability; and (2) in order to get a patent, an 
inventor must describe (enable) the invention in the published 
patent application in a way that would allow another person to 
make and use the invention.247 This enablement allows others 
to use the patent application to discover new improvements to 
the invention or technology, and patent law incentivizes 
improvements on known inventions and technology, further 
increasing the public’s benefit from the original patent.248 
Applying these concepts to the medical field, it follows that 
giving the benefits of patent protection to the inventors of 
medical technologies will increase the amount of benefit the 
public at large receives from the medical technology field.249 
However, there is some dispute as to whether the incentive to 
develop medical technologies such as Myriad’s gene sequences 
and diagnostic tests is greatly increased by the benefits of 
patenting those technologies.250 The research that leads to 
 243. Rosetta Genomics, supra note 183, at 14. 
 244. Id. at 29-30. See also Crouch, supra note 241 (describing Judge 
Sweet’s Myriad decision as against “standard thoughts on patentability.”). 
 245. U.S. CONST. art. 1, § 8, cl. 8. 
 246. See id. (securing, “for limited [t]imes,” the patent holder’s exclusive 
right to profit from those inventions and technologies). 
 247. 35 U.S.C. § 112 (2006). 
 248. See 35 U.S.C. § 101 (2006)  (granting patent eligibility to 
improvements upon previous patented inventions). 
 249. See Brian Murphy & Daniel Murphy, Bilski’s “Machine-or-
Transformation” Test: Uncertain Prognosis for Diagnostic Methods and 
Personalized Medicine Patents, 20 FORDHAM INTELL. PROP. MEDIA & ENT. L.J. 
755, 760 (2010) (suggesting that the incentive provided by a broad patent 
eligibility test is especially important in the fields of medicine and genetic 
diagnostics). 
 250. Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office 
(Myriad), 702 F. Supp. 2d 181, 210 (S.D.N.Y. 2010). 
 2011] MEDICINE AND PATENT LAW 841 
                                                          
many of these technologies receives federal funding in the form 
of grants or public university research.251 But further analysis 
indicates that medical technologies are not beyond the effects of 
patent incentivization. 
1. Patent Protection Incentives Are Important to University 
and Private Research 
Although their research is partially supported by public 
funds, universities are able to profit from that research,252 and, 
through patents, to prevent others from competing with 
them.253 Therefore, while the costs incurred by a university in 
developing patentable and profitable technologies may be more 
likely to be subsidized than those incurred by a private 
organization, universities’ ability to reap benefits from the 
patent system in the same way that private organizations do 
suggests that they are not impervious to the incentives it 
provides.254 Even assuming that university research efforts are 
largely unaffected by the incentives of the patent system does 
not defeat the importance of the patent system to their 
research, for, as their research is released into the public 
domain, private entities are free to develop improvements upon 
that research, creating more marketable technologies.255 
Without the incentives of the patent system, those private 
entities would be unable to recoup their research costs and 
would not improve university research in the public domain.256 
It is true that, even absent research assistance from public 
universities, private entities are often given research subsidies 
from public funds.257 But those funds help to research only the 
basic technologies of a patentable product; the cost of 
 251. See, e.g., id. (revealing that research for 63% of patents on gene 
sequences was partially funded by the government). Also relevant, is the fact 
that a public university is part owner of Myriad’s patents. Id. at 189–90. 
 252. See, e.g., Joe Kays & Arline Phillips-Han, Gatorade: The Idea That 
Launched an Industry, EXPLORE RESEARCH AT THE UNIVERSITY OF FLORIDA 
(Spring 2003), 
http://www.research.ufl.edu/publications/explore/v08n1/gatorade.html. 
 253. Property Rights: The Granting of Patents on Human Genes Has so far 
not Been the Disaster it Was Predicted To Be, 458 NATURE 386, 386 (2009). 
 254. It is true, however, that universities may do research that is never 
expected to result in a patentable product, but is simply released into the 
public. 
 255. 35 U.S.C. 101 (2006). 
 256. See Myriad, 702 F. Supp. 2d at 211. 
 257. See id. at 210. 
 842 MINN. J. L. SCI. & TECH. [Vol. 12:2 
 
                                                          
 
developing a commercially profitable application of that 
product is far greater and dwarfs the funding typically given to 
private research.258 Therefore, it is likely that, without the 
incentives of patent protection, the research assisted by federal 
subsidies will stop well short of anything useful to the public, 
because the costs would be prohibitive. 
2. The Public is Best Served by Maintaining the Incentives of 
Patent Protection to Medical Inventors 
Advanced medical tests, especially diagnostic DNA tests, 
can be very expensive.259 If the provider of a medical procedure 
is given a partial monopoly by patent protection, that provider 
will have more freedom in setting the price of the procedure.260 
Therefore, when several firms are providing a medical 
procedure, consumers will pay less for the procedure than if 
there were only one provider. Thus, if Myriad were not allowed 
to gain patent protection on its gene and diagnostic tests, those 
tests would be available to consumers at lower prices. 
The benefit of allowing patents for genes and resulting 
diagnostic tests is not much more complicated. If Myriad had 
known before sequencing the BRCA1 and BRCA2 genes that it 
would not be granted patents on them, it would not have 
performed the research.261 Retroactively taking patent 
protection away from a company that has already performed 
research and prepared the resulting genetic test will remove its 
monopoly of diagnostic testing and create competition to drive 
 258. See id. at 211. 
 259. Amy Dockser Marcus, Obsessed With Genes (Not Jeans), This Teen 
Analyzes Family DNA, WALL ST. J., Oct. 1, 2010, at A1. 
 260. Harold Demsetz, Why Regulate Utilities?, 11 J.L.  & ECON. 55, 56 
(1968). 
 261. Murphy, supra note 249, at 764. The costs of developing genetic tests 
can be hundreds of millions of dollars, while Myriad was only reported to have 
been given 22 million dollars in funding. Id. at 760–61; Ass’n for Molecular 
Pathology v. Myriad Genetics Inc. 09 Civ. 4515 at 49 (S.D.N.Y. 2010), 
available at http://www.aclu.org/files/assets/2010-3-29-AMPvUSPTO-
Opinion.pdf. A mistake was made in the Federal Supplement version of this 
case, misrepresenting the amount that Myriad received in funding. The 
original court opinion has been cited. Compare Ass’n for Molecular Pathology 
v. Myriad Genetics Inc. 09 Civ. 4515 at 49 (S.D.N.Y. 2010), available at 
http://www.aclu.org/files/assets/2010-3-29-AMPvUSPTO-Opinion.pdf (stating 
that Myriad had been given 22 million dollars in funding) with Myriad, 702 F. 
Supp. 2d at 201 (stating that Myriad had been given 122 million dollars in 
funding). 
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the cost of the tests down, but may prevent the development of 
future genetic tests for other cancers, or improved genetic tests 
for breast cancer. The long-term future consequences of 
removing patent protection for genetic tests can be illustrated 
by analyzing what would have happened if patent protection 
had never been offered for genes. Myriad would have been less 
willing to spend the vast amounts of money necessary to 
discover the sequences BRCA1 and BRCA2 genes and develop a 
marketable genetic test.262 This would prevent over 70,000 
women per year from being able to receive the BRCA1 and/or 
BRCA2 analysis.263 Moreover, without the patent incentive, 
many genes264 with important medical implications would 
never have been sequenced, and thus thousands of patients 
would be without the benefit of decades of medical research.265 
For example, currently 250,000 Americans suffer from a 
hereditary genetic neurological disease known as Huntington’s 
disease.266 Huntington’s disease causes neural degeneration, at 
first inhibiting an individual’s fine motor skills and eventually 
the ability to talk, reason, and remember.267 Huntington’s 
disease is completely linked to the gene; if a person has the 
gene, he or she will develop the disease, and die within twenty 
or fewer years.268 Most individuals do not develop symptoms of 
the disease until they are between thirty and fifty years of 
age—often after having children to whom they had a fifty 
percent chance of passing on the disease.269 The importance of 
genetic testing to families with a history of Huntington’s 
 262. See Rosetta Genomics, supra note 183, at 7 (suggesting that without 
patent protection, many gene based products will never reach the public). 
 263. Myriad charges approximately 3,000 dollars per test, and performed 
220,000,000 dollars worth of tests in 2008. Therefore, Myriad performed over 
70,000 tests in 2008. See Myriad, 702 F. Supp. 2d at 203. 
 264. The potential number of genes patents affected could be quite high, as 
40,000 genes have been patented. See Editorial: Property Rights: The Granting 
of Patents on Human Genes Has So Far Not Been the Disaster It Was Predicted 
to Be, 458 NATURE 386, 386 (2009). 
 265. See, e.g., Marsha L. Miller, HD Research - Past and Future, 
HUNTINGTON’S DISEASE SOCIETY OF AMERICA, 
http://www.hdsa.org/research/past-and-future.html (last visited June 11, 2011) 
(reporting that, since the discovery of the Huntington’s gene in 1993, an 
explosion of research has been performed regarding Huntington’s disease). 
 266. What is HD, HUNTINGTON’S DISEASE SOCIETY OF AMERICA, 
http://www.hdsa.org/about/our-mission/what-is-hd.html (last visited June 11, 
2011). 
 267. Id. 
 268. Id. 
 269. Id. 
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disease is clear, but without gene patent eligibility, the testing 
would likely not be available today.270 
Applying this illustration to future research elucidates the 
effects that stripping patent eligibility from genes may hinder 
genetic research and slow the development of medical 
innovation. This result would be devastating to future 
generations suffering from currently incurable genetic diseases 
or genetically linked diseases that cannot currently be 
diagnosed because the genes are undiscovered. Without patent 
protection, further research on both unidentified and identified 
genes and their effects would not be incentivized, potentially 
foreclosing treatments and cures for currently untreatable or 
incurable diseases such as breast cancer and Huntington’s 
disease.271 
On the other hand, it has been suggested that allowing 
patent protection for genes will allow patent holders to prevent 
further research on those genes, thus stunting genetic research 
more than a lack of incentive would.272 In reality this is highly 
unlikely; patent law is specifically designed to encourage 
improvements and innovations of currently patented inventions 
and technology.273 While some scientists may believe that gene 
patents would restrict their research,274 those scientists appear 
to be over-cautious because scientists being blocked from 
research is a nonissue.275 Even Myriad’s patents, the 
controversy of which is made clear by the existence of this case, 
has left research open to the public and has had almost no 
effect on BRCA1 and BRCA2 research.276 Indeed, since 
Myriad’s patents were granted, over 18,000 scientists have 
 270. Rosetta Genomics, supra note 183, at 7. 
 271. Id.; see also Murphy & Murphy, supra note 249, at 764. 
 272. Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office 
(Myriad), 702 F. Supp. 2d 181, 208 (S.D.N.Y. 2010).. 
 273. 35 U.S.C. § 101 (2006) (establishing that discoverers of improvements 
on previous inventions may patent those improvements). But see 35 U.S.C. § 
271 (2006) (establishing that patent holders can prevent the making, using or 
selling of their inventions). 
 274. Myriad, F. Supp. 2d at 208. 
 275. See Editorial, supra note 264, at 386. The editorial suggests that, even 
in cases where a scientist’s research could be hindered, legal workarounds are 
quite simple. 
 276. DEP’T OF HEALTH & HUMAN SERVS., REPORT OF THE SECRETARY’S 
ADVISORY COMMITTEE ON GENETICS, HEALTH, AND SOCIETY: GENE PATENTS 
AND LICENSING PRACTICES AND THEIR IMPACT ON PATIENT ACCESS TO 
GENETIC TESTS at 75 (2010). 
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conducted research on the BRCA1 and BRCA2 patents, 
resulting in over 7000 papers.277 It appears, then, that 
hindrance of future genetic research is not a reasonable policy 
argument against patenting genes. 
D. MYRIAD’S METHOD CLAIMS MAY NOT BE VALID UNDER §102 
OR §103 
Though it is clear public policy favors patenting of genes 
and the diagnostic tests based on those genes, and even if 
Myriad’s method claims are held to be patent eligible under  § 
101, affirming the district court’s invalidation of the claims on 
different grounds could be proper for novelty’s or 
nonobviousness’ sake.278 
1. Myriad’s Diagnostic Methods May Be Considered Not Novel 
As the Myriad opinion notes, all methods employed by 
Myriad in its diagnostic claims have been in the public domain 
for some time279 and are known and performed by scientists 
every day.280 Further, the processes used in Myriad’s diagnostic 
tests (isolating and sequencing DNA) are the same processes 
performed when locating and sequencing a gene, the necessary 
steps for patenting a gene. Therefore, these steps have been 
well known since at least 1990, the start of the Human Genome 
Project.281 Given that Myriad’s first patent application was not 
until 1994,282 this creates a large novelty obstacle to holding 
Myriad’s method claims valid.283 That these particular 
diagnostic procedures have never been performed before with 
 277. Rosetta Genomics, supra note 183, at 15. Of particular interest is the 
fact that several of the plaintiffs complaining that gene patents block genetic 
research have themselves published over 48 papers on the very genes Myriad 
has patented. Id. 
 278. 35 U.S.C. §§ 102–03 (2006). If Myriad’s process claims are found 
invalid, a further argument could be made against the composition of matter 
claims: without any way to prosper from the genes, the genes would not be 
useful aside from their benefits to the public domain. As usefulness is a 
condition of patent eligibility, this may create a bar to the composition of 
matter claims. 35 U.S.C. § 101 (2006). This line of reasoning is beyond the 
scope of this comment, though could be addressed in further publications. 
 279. Myriad, 702 F. Supp. 2d at 200. 
 280. Id. 
 281. Id. at 193. 
 282. Id. at 212 n.26. 
 283. See 35 U.S.C. § 102 (establishing that any procedure that was in use 
by the public more than one year before the patent’s application date is not 
novel). 
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this particular gene may influence the reviewing court, 
especially given the public policy interests and the deference to 
USPTO determinations.284 Whatever the court’s determination 
on the issue, an opinion validating or invalidating Myriad’s 
method claims should address this issue. 
2. Myriad’s Diagnostic Methods and Compositions of Matter 
May Be Considered Obvious 
Even if a court does not invalidate Myriad’s diagnostic 
methods for novelty reasons, the obstacle of obviousness will 
remain for both the diagnostic methods and the compositions of 
matter. Arguments are strong for both a finding of obviousness 
and nonobviousness. Under § 103, an invention is obvious when 
a person of ordinary skill in the art would have known how to 
produce and patent the article under scrutiny as of the date of 
the invention.285 The determination of whether an invention is 
obvious may involve consideration of the commercial success of 
the patented article, “[the] long felt but unsolved needs, failure 
of others, etc.”286  Because the processes used in Myriad’s 
diagnostic tests are used by scientists every day,287 it is 
reasonable that they would be obvious to someone “of ordinary 
skill in the [field].”288 
However, it is also reasonable that if the diagnostic 
methods escape the novelty rejection because the methods had 
never been applied to this particular gene, the court may also 
overlook an obviousness rejection based on the same argument. 
This is especially true because the knowledge that makes it 
obvious to apply the method to this gene is the gene’s sequence, 
which was not known by those of ordinary skill in the art until 
the patent application was published. Patent law indeed holds 
an obviousness exception when a biotechnology method, as 
here, is applied to a composition of matter patented at the same 
time, but the methods listed in the statute do not seem to 
encompass diagnostic testing.289 
This leads to Myriad’s composition of matter claims. 
 284. Supra notes 259–268 and accompanying text; supra notes 226–227 
and accompanying text. 
 285. See Graham v. John Deere Co., 383 U.S. 1, 17–18 (1966). 
 286. Id. 
 287. Myriad, 702 F. Supp. 2d at 200. 
 288. 35 U.S.C. § 103 (2006). 
 289. 35 U.S.C. § 103(b). 
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Because Myriad’s claims resulted in an invention with great 
commercial success, 290 and because many others attempted but 
failed to develop the same invention,291 there some merit to the 
argument that Myriad’s invention was not obvious.292 However, 
many of ordinary skill in Myriad’s field realized the need for 
the invention293 and there are only so many possible sequences 
the BRCA1 and BRCA2 genes could have expressed, therefore 
the composition of matter patents may be found obvious to 
try.294 On the other hand, while there is a finite number of 
possible sequences for the BRCA1 and BRCA2 genes, one who 
is trying to discover a gene can assume that it is thousands of 
base pairs long,295 and because each position could be held one 
of four nucleotides, the number of possible sequences for any 
one gene is enormous.296 Therefore, a court could also find that, 
though the prior art gives guidance as to the form of the 
invention, the only way to discover the invention is to throw 
darts at a board composed of all possibilities, and therefore 
being obvious to try would not give rise to obviousness.297 
The Federal Circuit considered this argument in Kubin, 
and found that determining a gene sequence was indeed 
obvious because it was obvious to try.298 However, in that case, 
the applicant started off knowing the sequence of the one 
protein for which the gene encoded, from which they could work 
backwards to determine the sequence of the gene.299 Being able 
to work backwards from an expressed gene product to the gene 
would be a far more predictable, and profoundly less similar to 
throwing darts at a board of composition of matter possibilities 
 290. Myriad, 702 F. Supp. 2d at 203 (stating that Myriad made over 200 
million dollars in revenue from their diagnostic tests in 2008). 
 291. Id. at 201–02 (stating that multiple other groups were attempting to 
develop the claimed invention at issue, but that they did not succeed before 
Myriad). 
 292. See Graham v. John Deere Co., 383 U.S. 1, 17–18 (1966) (suggesting 
that the long-felt need for an intention and the failed attempts of others may 
be useful in the determination of obviousness). 
 293. See Myriad, 702 F. Supp. 2d at 201 (describing the funds and efforts 
that several research teams across the world put into being the first to 
discover the sequence of the BRCA1 gene). 
 294. Supra notes 110–111 and accompanying text. 
 295. See Myriad, 702 F. Supp. 2d at 194 (stating that a typical gene is 
thousands of nucleotides long). 
 296. Supra note 27 and accompanying text. 
 297. In re Kubin, 561 F.3d 1351, 1359 (Fed. Cir. 2009). 
 298. Id. at 1361. 
 299. Id. at 1360. 
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than would sequencing a gene from scratch.300 Therefore, it 
appears that the obviousness of Myriad’s composition of matter 
claim could be resolved in either direction. 
V. CONCLUSION 
It is unwise to blithely remove patent eligibility from fields 
in which incentives for innovation have a dramatically positive 
effect on the population as a whole. Patent law was established 
to incentivize inventions that are useful to the public, while 
still allowing fair access to innovations. Because the public 
benefit resulting from incentivizing gene patents far outweighs 
the potential for public loss, it is in the country’s best interest 
to structure and interpret patent law to find genes and 
methods employing them patent eligible. 
Unfortunately, patenting genes is a controversial issue 
right now, and the courts cannot decide patent eligibility on the 
basis of public policy alone. Patent law does allow for an 
interpretation that would find genes and the methods 
employing them patent eligible, but those methods are likely to 
encounter novelty and obviousness rejections that they may be 
unable to overcome. Currently, patent law does not provide a 
clear solution. 
This Comment suggests that the Court of Appeals for the 
Federal Circuit should reverse the district court’s decision in 
Myriad on all counts. However, it is the stance of this Comment 
that patent law does not provide enough clarity for gene 
patents, especially where methods are concerned. Therefore, 
any decision made by this court and the Supreme Court on 
gene patent eligibility should include an appeal to Congress to 
amend the current patent laws to provide more and clearer 
protection to gene patents in terms of patent eligibility, novelty, 
and obviousness. 
The Association for Molecular Pathology, and other 
research organizations should also appeal to Congress. 
Although Congress has shown unwillingness to outlaw gene 
patents, researchers may be placated by a compromise that 
would protect their interests. Mandatory licensing of all gene 
patents to not-for-profit researchers, for example, would allow 
 300. See id. (suggesting that those skilled in the art would consider 
working backwards from a known protein sequence to determine the gene 
coding for it to be “profoundly predictable.”). 
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public research into genes, while protecting the genetic 
diagnosis industry. Whatever the result in the Myriad appeal, 
the continuing market for patents in genes and genetic 
diagnostic tests, and the medical advances that could follow 
will depend on a system of patent law more appropriate for the 
advancing field of genetics. 
 
